Home

arrow iconNewsarrow iconarrow icon

Can AI Pick IVF Embryos Better Than Humans?

Can AI Pick IVF Embryos Better Than Humans?

A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.

By FertilityIn

29 Apr 2026

4 min read

AI Birth, AI Pick IVF Embryos

AI Birth, AI Pick IVF Embryos

The Race for Precision in IVF

In the high-stakes world of In Vitro Fertilization (IVF), the decision of which embryo to transfer can be the difference between a successful pregnancy and heartbreak. For decades, this immense responsibility has rested on the experienced shoulders of clinical embryologists, who meticulously analyze embryos under a microscope. But a new contender has entered the lab: Artificial Intelligence.


A major new study published in Nature Medicine has finally provided a rigorous answer to the question on everyone's mind: Can AI-driven embryo selection accuracy outperform human expertise? The results are in, and while they might surprise you, they paint a promising future for aspiring parents.


The Study: AI vs. Human Expertise

The research, led by Dr. Peter Illingworth and a global team of scientists, was a randomized, double-blind, non-inferiority trial conducted across 14 IVF clinics in Australia and Europe. It represents one of the most comprehensive real-world tests of deep learning in reproductive medicine to date.​

The study compared two methods of selection:

  1. The Human Approach: Experienced embryologists using standard morphological assessment (Gardner grading) to choose the best blastocyst.
  2. The AI Approach: A deep learning algorithm known as iDAScore (developed by Vitrolife), which analyzed time-lapse images to generate a viability score.

The trial involved women under 42 years of age with at least two viable blastocysts. The goal was to see if the AI could match or beat the clinical pregnancy rates achieved by humans.​


The Verdict: Comparable Accuracy, Unmatched Speed

The findings revealed that AI is not yet the "magic bullet" that drastically increases pregnancy rates overnight, but it is a highly competent assistant.

  • Pregnancy Rates: The clinical pregnancy rate for the AI-selected group was 46.5%, compared to 48.2% for the embryologist-selected group.
  • Statistical Significance: The difference was statistically insignificant, meaning the AI performed effectively on par with human experts in a real-world clinical setting.​

While the AI did not demonstrate "superiority" in raw pregnancy numbers, it matched the high standards of human care. This is a critical validation for AI-driven embryo selection accuracy, proving it is safe and reliable.


The Real Revolution: 10x Faster Workflow

If the success rates are similar, why switch to AI? The answer lies in efficiency. The study found that the AI system was significantly faster than its human counterparts.

  • Speed: The AI required far less time to assess embryos, completing the selection process 10 times faster than embryologists.​
  • Consistency: Unlike humans, who may suffer from fatigue or subjective bias after hours of analysis, the AI provides an objective, standardized score every single time.​

This efficiency could be a game-changer for busy clinics. By automating the time-consuming selection process, embryologists can free up valuable time to focus on complex procedures like micromanipulation and patient interaction, potentially reducing burnout and improving overall lab workflow.


What This Means for Patients

For patients undergoing IVF, these findings offer reassurance and hope.

  • Standardization: AI offers a "second opinion" that is objective and data-driven, reducing the variability between different clinics or individual embryologists.
  • Access: As AI tools become more prevalent, they could help democratize high-quality care, ensuring patients in smaller clinics receive the same level of embryo assessment as those in major research centers.
  • Future Potential: This is just version 1.0. As deep learning models ingest more data, their ability to detect subtle features invisible to the human eye, such as metabolic activity or genetic likelihood—will likely improve, potentially raising success rates in the future.


Conclusion

So, can AI pick IVF embryos better than humans? In terms of raw pregnancy outcomes today, the answer is "not yet." However, in terms of speed, consistency, and workflow efficiency, AI is already winning. As AI-driven embryo selection accuracy continues to evolve, the partnership between human expertise and machine learning will likely become the new gold standard in fertility care, bringing us one step closer to helping more families grow.

43 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.

ART

1 min read

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.

ART

1 min read

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.

ART

1 min read

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.

ART

1 min read

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.

ART

1 min read

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.

ART

1 min read

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address